Study analysis · Endocrinology · 2007
A hormone shot made diabetic monkeys' blood sugar plummet for 6 weeks — without the dangerous crashes doctors fear.
Giving diabetic monkeys a hormone called FGF-21 every day for six weeks improved their blood sugar, cholesterol, and weight without causing low blood sugar.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study gave a substance to diabetic monkeys and saw their health markers improve. But because there was no comparison group, we can't be sure the substance caused the improvements. It's an early step, not proof it works in people.
What’s the bottom line?
Scientists gave a hormone called FGF-21 to diabetic monkeys every day for 6 weeks. The monkeys' blood sugar, triglycerides, insulin, and glucagon all dropped a lot. Their cholesterol levels improved, and they lost a little weight. Importantly, their blood sugar never got too low.
How strong is this study?
The study is not very strong because we don't know if they compared to monkeys who didn't get the substance, and we only have a short summary. So we should be cautious about trusting the results.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
13 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample sizeno sample size reported
- Follow-up+10/10
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 57 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. No control group, randomization, or blinding reported. Animal model (diabetic rhesus monkeys) limits human applicability. Abstract only, so methodology cannot be verified. Cannot rule out confounding, natural progression, or placebo effects.
COI Unknown
Could not determine conflict of interest status
No conflicts of interest or funding information are provided in the text, so potential conflicts cannot be assessed.
The text is an abstract without a conflict of interest, funding, or author affiliation section. The study appears to test a potential therapeutic agent, but no financial relationships are disclosed. Thus, any industry funding or author conflicts remain unknown.
Key takeaways
- 01
After 6 weeks of daily FGF-21, diabetic monkeys had dramatic drops in fasting blood sugar, fructosamine, triglycerides, insulin, and glucagon.
- 02
Their LDL (bad) cholesterol went down and HDL (good) cholesterol went up.
- 03
They also lost a small but significant amount of weight.
- 04
No hypoglycemia occurred.
- 05
This study was in monkeys, not humans.
- 06
The abstract does not report absolute risk numbers or effect sizes, so we cannot say how many extra cases or what the absolute improvement was.
- 07
The results suggest FGF-21 might help human diabetics, but more research is needed.
Surprising findings
- No hypoglycemia was observed despite dramatic reductions in fasting plasma glucose.Many drugs that lower blood sugar aggressively can cause dangerous hypoglycemia, so a potent glucose-lowering effect without crashes is counterintuitive.
- FGF-21 caused a small but significant weight loss rather than weight gain.Some diabetes treatments, like insulin and sulfonylureas, are associated with weight gain, so a therapy that lowers glucose while promoting weight loss is notable.
Practical takeaways
Do not try to obtain or use FGF-21 as a diabetes treatment based on this study.
This is an animal study in diabetic rhesus monkeys; the abstract does not report human data, dosing, safety, or efficacy. Full paper was not available for verification.
low confidenceFor those tracking diabetes drug development, FGF-21 analogs may be a research target to follow in future clinical trials.
The abstract only supports further development, not proven human benefit. No human trial results are described.
low confidenceWhy this study matters
Monkey Blood Sugar Plummets
Daily FGF-21 for 6 weeks caused a dramatic decline in fasting plasma glucose, fructosamine, triglycerides, insulin, and glucagon in diabetic rhesus monkeys. The abstract does not report absolute effect sizes, percentages, or confidence intervals, so the exact magnitude is not specified.
Diabetes drugs often target one or two of these markers, but FGF-21 appeared to improve multiple metabolic problems at once.
No Hypoglycemia — A Big Safety Signal
Despite the dramatic glucose lowering, hypoglycemia was not observed at any point during the study. This is notable because many glucose-lowering therapies risk dangerously low blood sugar.
Hypoglycemia is a major fear for people with diabetes and a common reason treatments fail or require careful monitoring.
Cholesterol and Heart Markers Improved
FGF-21 administration led to significant improvements in lipoprotein profiles: lower LDL cholesterol, higher HDL cholesterol, and beneficial changes in circulating cardiovascular risk markers/factors. Specific numbers are not given in the abstract.
Heart disease is a leading cause of death in people with diabetes, so improvements beyond glucose matter greatly.
Small but Significant Weight Loss
The study induced a small but significant weight loss in the diabetic monkeys. The abstract does not specify how much weight was lost or over what period beyond the 6-week treatment.
Many diabetes treatments cause weight gain, so a therapy that promotes even modest weight loss could be attractive.
From Rodents to Primates — A Translation Step
Previous rodent studies showed FGF-21 lowered glucose and triglycerides. This study tested it in non-genetically modified diabetic rhesus monkeys to better gauge potential human efficacy. It is still an animal study, not a human trial.
Primate data are closer to humans than rodent data, but many promising animal results still fail in people.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists gave a hormone called FGF-21 to diabetic monkeys every day for 6 weeks. The monkeys' blood sugar, triglycerides, insulin, and glucagon all dropped a lot. Their cholesterol levels improved, and they lost a little weight. Importantly, their blood sugar never got too low.
Research results
After 6 weeks of daily FGF-21, diabetic monkeys had dramatic drops in fasting blood sugar, fructosamine, triglycerides, insulin, and glucagon. Their LDL (bad) cholesterol went down and HDL (good) cholesterol went up. They also lost a small but significant amount of weight. No hypoglycemia occurred.
What this means - more context
This study was in monkeys, not humans. The abstract does not report absolute risk numbers or effect sizes, so we cannot say how many extra cases or what the absolute improvement was. The results suggest FGF-21 might help human diabetics, but more research is needed.
To explore the therapeutic properties of FGF-21 in a non-genetically modified primate species (diabetic rhesus monkeys) and demonstrate potential efficacy in humans.
Daily administration of FGF-21 for 6 weeks to diabetic rhesus monkeys caused a dramatic decline in fasting plasma glucose, fructosamine, triglycerides, insulin, and glucagon. Hypoglycemia was not observed. FGF-21 also improved lipoprotein profiles (lower LDL, higher HDL), produced beneficial changes in cardiovascular risk markers, and induced small but significant weight loss. The authors conclude these data support development of FGF-21 for diabetes treatment.
Methods Used
FGF-21 was administered daily for 6 weeks to diabetic rhesus monkeys. The abstract does not specify sample size, control group, randomization, or blinding. Methodology details not available in abstract.
Main Finding
FGF-21 dramatically reduced fasting plasma glucose, fructosamine, triglycerides, insulin, and glucagon without causing hypoglycemia. It also improved lipoprotein profiles, cardiovascular risk markers, and caused small but significant weight loss. Absolute risk or effect sizes not reported in abstract.
Confidence Level
Limited - based on abstract only, full methodology not available. This is an animal study; results may not translate to humans.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •No control group mentioned in abstract
- •Animal study - results may not translate to humans
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
No hypoglycemia was observed despite dramatic reductions in fasting plasma glucose.
Many drugs that lower blood sugar aggressively can cause dangerous hypoglycemia, so a potent glucose-lowering effect without crashes is counterintuitive.
Practical Takeaways
Do not try to obtain or use FGF-21 as a diabetes treatment based on this study.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 57 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Animal Cohort Study
Subject
Lower probability
on the GRADE evidence scale
This study gave a substance to diabetic monkeys and saw their health markers improve. But because there was no comparison group, we can't be sure the substance caused the improvements. It's an early step, not proof it works in people.
Strengths
- In vivo nonhuman primate model (closer to human physiology than rodents)
- Longitudinal administration over 6 weeks
- Multiple metabolic and safety outcomes measured
Weaknesses
- Full methodology not available - based on abstract only
- No control group mentioned
- Randomization unknown
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists gave a hormone called FGF-21 to diabetic monkeys every day for 6 weeks. The monkeys' blood sugar, triglycerides, insulin, and glucagon all dropped a lot. Their cholesterol levels improved, and they lost a little weight. Importantly, their blood sugar never got too low.
Research results
After 6 weeks of daily FGF-21, diabetic monkeys had dramatic drops in fasting blood sugar, fructosamine, triglycerides, insulin, and glucagon. Their LDL (bad) cholesterol went down and HDL (good) cholesterol went up. They also lost a small but significant amount of weight. No hypoglycemia occurred.
What this means - more context
This study was in monkeys, not humans. The abstract does not report absolute risk numbers or effect sizes, so we cannot say how many extra cases or what the absolute improvement was. The results suggest FGF-21 might help human diabetics, but more research is needed.
To explore the therapeutic properties of FGF-21 in a non-genetically modified primate species (diabetic rhesus monkeys) and demonstrate potential efficacy in humans.
Daily administration of FGF-21 for 6 weeks to diabetic rhesus monkeys caused a dramatic decline in fasting plasma glucose, fructosamine, triglycerides, insulin, and glucagon. Hypoglycemia was not observed. FGF-21 also improved lipoprotein profiles (lower LDL, higher HDL), produced beneficial changes in cardiovascular risk markers, and induced small but significant weight loss. The authors conclude these data support development of FGF-21 for diabetes treatment.
Methods Used
FGF-21 was administered daily for 6 weeks to diabetic rhesus monkeys. The abstract does not specify sample size, control group, randomization, or blinding. Methodology details not available in abstract.
Main Finding
FGF-21 dramatically reduced fasting plasma glucose, fructosamine, triglycerides, insulin, and glucagon without causing hypoglycemia. It also improved lipoprotein profiles, cardiovascular risk markers, and caused small but significant weight loss. Absolute risk or effect sizes not reported in abstract.
Confidence Level
Limited - based on abstract only, full methodology not available. This is an animal study; results may not translate to humans.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •No control group mentioned in abstract
- •Animal study - results may not translate to humans
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
No hypoglycemia was observed despite dramatic reductions in fasting plasma glucose.
Many drugs that lower blood sugar aggressively can cause dangerous hypoglycemia, so a potent glucose-lowering effect without crashes is counterintuitive.
Practical Takeaways
Do not try to obtain or use FGF-21 as a diabetes treatment based on this study.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 57 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Animal Cohort Study
Subject
Lower probability
on the GRADE evidence scale
This study gave a substance to diabetic monkeys and saw their health markers improve. But because there was no comparison group, we can't be sure the substance caused the improvements. It's an early step, not proof it works in people.
Strengths
- In vivo nonhuman primate model (closer to human physiology than rodents)
- Longitudinal administration over 6 weeks
- Multiple metabolic and safety outcomes measured
Weaknesses
- Full methodology not available - based on abstract only
- No control group mentioned
- Randomization unknown
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study is not very strong because we don't know if they compared to monkeys who didn't get the substance, and we only have a short summary. So we should be cautious about trusting the results.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
13 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample sizeno sample size reported
- Follow-up+10/10
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 57 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. No control group, randomization, or blinding reported. Animal model (diabetic rhesus monkeys) limits human applicability. Abstract only, so methodology cannot be verified. Cannot rule out confounding, natural progression, or placebo effects.
COI Unknown
Could not determine conflict of interest status
No conflicts of interest or funding information are provided in the text, so potential conflicts cannot be assessed.
The text is an abstract without a conflict of interest, funding, or author affiliation section. The study appears to test a potential therapeutic agent, but no financial relationships are disclosed. Thus, any industry funding or author conflicts remain unknown.
Standing
The people behind it
The researchers who wrote the study this analysis is built on.
Authored by
9 researchersIf this is your work, this is how we attribute it on Fit Body Science. Alexei Kharitonenkov is listed as the lead author.